Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–27 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Maternal Immunization Clear all

Withdrawn Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

NCT03191383

View directory record Official record

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only

Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Newton, Kansas • Syracuse, New York • Ellensburg, Washington

Source: ClinicalTrials.gov public record

Updated Oct 14, 2018 · Synced May 22, 2026, 4:11 AM EDT

Completed Phase 3 Interventional

A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)

NCT00000751

View directory record Official record

Conditions: HIV Infections, Pregnancy
Interventions: Anti-HIV Immune Serum Globulin (Human), Globulin, Immune, Zidovudine; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 13 Years to 60 Years · Female only

Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 48
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 26 more

Source: ClinicalTrials.gov public record

Updated Sep 29, 2008 · Synced May 22, 2026, 4:11 AM EDT

Completed No phase listed Observational Accepts healthy volunteers

COVID Booster in Pregnancy and Lactation

NCT05543993

View directory record Official record

Conditions: COVID-19
Interventions: Bivalent COVID-19 Booster; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 13 Years to 55 Years · Female only

Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Dec 1, 2025 · Synced May 22, 2026, 4:11 AM EDT